Comparative Pharmacology
Head-to-head clinical analysis: AMILORIDE HYDROCHLORIDE versus TRIAMTERENE AND HYDROCHLOROTHIAZIDE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: AMILORIDE HYDROCHLORIDE versus TRIAMTERENE AND HYDROCHLOROTHIAZIDE.
AMILORIDE HYDROCHLORIDE vs TRIAMTERENE AND HYDROCHLOROTHIAZIDE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Amiloride hydrochloride is a potassium-sparing diuretic that blocks epithelial sodium channels (ENaC) in the distal convoluted tubule and collecting duct of the nephron, inhibiting sodium reabsorption and reducing potassium and hydrogen ion secretion.
Triamterene inhibits sodium reabsorption in the distal renal tubules by blocking epithelial sodium channels, reducing potassium excretion. Hydrochlorothiazide inhibits sodium and chloride reabsorption in the distal convoluted tubule by binding to the thiazide-sensitive sodium-chloride cotransporter, leading to increased diuresis and natriuresis.
5-10 mg orally once daily; maximum 20 mg/day.
Adults: 1 capsule (triamterene 37.5 mg / hydrochlorothiazide 25 mg) orally once daily or twice daily; maximum triamterene 150 mg/day.
None Documented
None Documented
Terminal elimination half-life is 6-9 hours; prolonged to 20-24 hours in renal impairment
Triamterene: 1.5-2.5 hours (terminal), prolonged in hepatic impairment; Hydrochlorothiazide: 6-15 hours (terminal), prolonged in renal impairment.
Renal, approximately 50% unchanged; minor biliary/fecal elimination (<10%)
Triamterene: renal 21-50% (unchanged) and 40-54% (metabolites); Hydrochlorothiazide: renal >95% unchanged.
Category C
Category A/B
Potassium-Sparing Diuretic
Potassium-Sparing Diuretic